Last reviewed · How we verify
pirfenidone and nintedanib
At a glance
| Generic name | pirfenidone and nintedanib |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants (PHASE1)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
- Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PHASE4)
- Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients (PHASE1)
- To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (PHASE2)
- A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pirfenidone and nintedanib CI brief — competitive landscape report
- pirfenidone and nintedanib updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI